These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1417013)

  • 21. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
    Eguchi F; Taguchi T; Furue H; Ikeda M; Tsukakoshi S;
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1423-9. PubMed ID: 11681251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research.
    Tonato M
    Eur J Cancer; 1991; 27 Suppl 1():S12-4; discussion S22. PubMed ID: 1831628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR; Serrou B; Caubel M
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
    Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
    J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis.
    Moens P; Levarlet M; Hendrickx P; De Guchteneere E
    Acta Anaesthesiol Belg; 1997; 48(4):245-50. PubMed ID: 9526603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
    Sampi K; Taguchi T
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):922-8. PubMed ID: 2140498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms].
    Saur P; Mühr C; Kazmaier S; Neumann P; Buhre W
    Anaesthesiol Reanim; 1996; 21(5):131-5. PubMed ID: 9044556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ondansetron against metoclopramide/dexamethasone--a comparative study.
    Lim AK; Haron MR; Yap TM
    Med J Malaysia; 1994 Sep; 49(3):231-8. PubMed ID: 7845271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy.
    Spector JI; Lester EP; Chevlen EM; Sciortino D; Harvey JH; Whaley W; Madajewicz S; Isaacs R; Homesley HD; Yee S; Beck TM; Tchekmedyian NS; Crawford KH; Ames M; Creed MR
    Oncologist; 1998; 3(6):432-438. PubMed ID: 10388135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
    Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
    J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
    Grunberg SM; Lane M; Lester EP; Sridhar KS; Mortimer J; Murphy W; Sanderson PE
    Cancer Chemother Pharmacol; 1993; 32(4):268-72. PubMed ID: 8324868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
    Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
    Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
    Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
    Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
    Fumoleau P; Giovannini M; Rolland F; Votan B; Paillarse JM
    Oral Oncol; 1997 Sep; 33(5):354-8. PubMed ID: 9415336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
    Krzakowski M; Graham E; Goedhals L; Joly F; Pawlicki M; Rapoport B; Yelle L; Lees J; McQuade B
    Anticancer Drugs; 1998 Aug; 9(7):593-8. PubMed ID: 9773802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.